Therapeutic Electromagnetic Field (TEMF) and Gamma Irradiation  on Human Breast Cancer Xenograft Growth, Angiogenesis and Metastasis by Cameron, Ivan L. et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
7-26-2005
Therapeutic Electromagnetic Field (TEMF) and
Gamma Irradiation on Human Breast Cancer
Xenograft Growth, Angiogenesis and Metastasis
Ivan L. Cameron
LuZhe Sun
Nicholas Short
W. Elaine Hardman
Marshall University, hardmanw@marshall.edu
C. Douglas Williams
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Medical
Biochemistry Commons, Medical Cell Biology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Cameron IL, Sun LZ, Short N, Hardman WE, Williams CD: Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on
human breast cancer xenograft growth, angiogenesis and metastasis. Cancer Cell Int 2005, 5:23.
BioMed Central
C
TIONALINTERNA
ANCER CELL
Page 1 of 13
(page number not for citation purposes)
Cancer Cell International
Open AccessPrimary research
Therapeutic Electromagnetic Field (TEMF) and gamma irradiation 
on human breast cancer xenograft growth, angiogenesis and 
metastasis
Ivan L Cameron*1, Lu-Zhe Sun1, Nicholas Short1, W Elaine Hardman2 and C 
Douglas Williams3
Address: 1Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San 
Antonio, Texas 78229, USA, 2Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, Louisiana 
70808, USA and 3EMF Therapeutics, Inc., P.O. Box 679, Signal Mountain, Tennessee 37377, USA
Email: Ivan L Cameron* - cameron@uthscsa.edu; Lu-Zhe Sun - sunl@uthscsa.edu; Nicholas Short - nshort@rice.edu; W 
Elaine Hardman - hardmawe@pbrc.edu; C Douglas Williams - dwilliams@bouldincorp.com
* Corresponding author    
electromagnetic fieldbreast cancerionizing irradiationangiogenesismetastasis
Abstract
Background: The effects of a rectified semi-sinewave signal (15 mT amplitude, 120 pulses per
second, EMF Therapeutics, Inc.) (TEMF) alone and in combination with gamma irradiation (IR)
therapy in nude mice bearing a human MDA MB231 breast cancer xenograft were tested. Green
fluorescence protein transfected cancer cells were injected into the mammary fat pad of young
female mice. Six weeks later, mice were randomly divided into four treatment groups: untreated
controls; 10 minute daily TEMF; 200 cGy of IR every other day (total 800 cGy); IR plus daily TEMF.
Some mice in each group were euthanized 24 hours after the end of IR. TEMF treatment continued
for 3 additional weeks. Tumor sections were stained for: endothelial cells with CD31 and PAS or
hypoxia inducible factor 1α (HIF).
Results: Most tumors <35 mm3 were white but tumors >35 mm3 were pink and had a vascularized
capsule. The cortex within 100 microns of the capsule had little vascularization. Blood vessels,
capillaries, and endothelial pseudopods were found at >100 microns from the capsule (subcortex).
Tumors >35 mm3 treated with IR 24 hours previously or with TEMF had decreased blood vessels
in the subcortex and more endothelial pseudopods projecting into hypoxic, HIF positive areas than
tumors from the control group. Mice that received either IR or TEMF had significantly fewer lung
metastatic sites and slower tumor growth than did untreated mice. No harmful side effects were
attributed to TEMF.
Conclusion: TEMF therapy provided a safe means for retarding tumor vascularization, growth and
metastasis.
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Background
In a previously published experimental research report, it
was found that exposing a transplantable murine mam-
mary adenocarcinoma to a 15 mT EMF given at 120 pulses
per second for 10 minutes per day significantly reduced
tumor growth and vascularization and resulted in an
increased survival time [1]. This published report appears
to be the only literature available on the use of pulsating
magnetic fields to reduce tumor angiogenesis. The authors
of this report suggested that the magnetic field treatment
used acted to reduce tumor angiogenesis and might have
value as an alternative therapeutic modality for treatment
of patients with tumors. The study reported here was
designed to further investigate the potential of the same
EMF therapy to inhibit growth and angiogenesis of a
human breast cancer xenograft and to compare the effects
of: 1) a commonly used course of gamma irradiation (IR)
involving exposure to 200 cGy every second day for a total
of 800 cGy, 2) daily exposure to TEMF, and 3) a combina-
tion of these two therapeutic treatment regimens on
tumor growth, tumor angiogenesis, tumor metastasis, and
of the side effects of each treatment regimen. Although
this study used whole body IR therapy, most IR therapy of
human patients is restricted to localized targeted regions
of the body to avoid general side effects of IR treatment.
The MDA MB231 cancer cell line transfected with and
expressing a green fluorescent protein (GFP) gene was
used to facilitate study of metastases of cancer cells from
the site of the primary tumor [2].
Our study results demonstrate the potential of TEMF ther-
apy to retard tumor: growth, angiogenesis, and metastasis,
without harmful side effects.
Results
Body Weight
Once the mice were divided into treatment groups the
body weight of each mouse was measured every 3 to 4
days for the remainder of the experiment. As illustrated in
Fig. 1, the two groups that received IR therapy every sec-
ond day for 8 days demonstrated a mean body weight loss
beginning during IR therapy and lasting until about 8 or
9 days after the end of IR therapy. After completion of the
IR therapy, the irradiated mice again began to regain their
weight toward the mean weight of the two groups of mice
not subjected to IR therapy. The group of mice that
received only EMF therapy demonstrated a continuous
increase in mean body weight similar to the group of mice
given no therapy.
Tumor Growth
Fig. 2 illustrates mean tumor volume change for each of
the four treatment groups starting at the beginning of IR
and/or EMF therapy. All tumors in each therapy group
were less than 35 mm3 at the start of treatment period. To
statistically assess tumor growth rate, the data on each
tumor in each group of mice was subjected to linear
regression analysis. Tumor volume gave a good fit to a lin-
ear regression model. The slope (growth rate) derived
from the linear regression of each tumor volume was used
to determine any statistical differences in growth rates
between treatment groups (Fig. 2). Growth rate of tumors
from the untreated group was significantly faster (p <
0.001) than any of the three groups of treated mice. The
tumor growth rate of the group of mice treated solely with
EMF therapy was significantly less than the tumor growth
rate of the untreated group. The tumor growth rates of the
two groups of mice treated with gamma irradiation were
significantly less than the tumor growth rates of the
untreated or TEMF only treated groups.
Results of an evaluation of the tumor growth rates from
day 7 though day 15 post IR treatment are reported in Fig.
3. As illustrated in Fig. 3, the mean tumor growth rate of
mice given neither IR nor TEMF treatment was signifi-
cantly higher than the three groups given IR and TEMF
therapy either alone or in combination. The group of mice
given both IR and TEMF followed by daily TEMF had a
mean tumor growth rate significantly lower than that of
the other three groups. Clearly, the continued application
of daily TEMF therapy following IR therapy had an addi-
tive inhibitory effect on the tumor growth rate during the
7 to 15 days after the course of IR therapy.
Tumor vasculature
While making measurements on tumor volume, tumor
color was observed through the skin of the nude mice.
After recording tumor color and volume of each mouse, it
became clear that smaller tumors were white while larger
tumors were pink. Fig. 4 illustrates the relationship
between tumor color and tumor volume. Almost all
tumors less than 35 mm3 were white whereas tumors
greater than approximately 35 mm3 were pink in color.
Application of the pressure from one's finger to a pink
tumor followed by the rapid removal of the finger pres-
sure showed a rapid color change from white to pink.
Histological examination of midsections of PAS stained
tumors was done to assess tumor vascularization patterns.
Tumors with a volume >35 mm3 demonstrated a connec-
tive tissue capsule with blood vessels (Fig. 5A). At higher
magnification the cortical area within about 100 µm of
the capsule revealed few blood vessels while the area
greater than 100 µm from the capsule showed evidence of
considerable blood vessel and capillaries with many
endothelial pseudopods extending away from the capil-
laries (Fig. 5B&5C). The general direction of the pseudo-
pods was parallel to the tumor capsule surface.
Immunohistochemical localization of CD-31, used as a
specific marker of endothelium, demonstrated a positive
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reaction of pseudopods (Fig. 5D). Areas of tumor necrosis
were observed, below the subcortical area (Fig. 5E&5F).
Immunohistochemical localization of hypoxia-inducible
factor 1-α (HIF) reveals the subcortical area of the tumor
to contain HIF positive cells while the tumor capsule, cor-
tex and necrotic areas of the tumor demonstrate no evi-
dence of HIF. Thus, the area found to be HIF positive were
enriched in endothelial pseudopods.
Ocular grid intercept couting was used to quantify tumor
vascularization in 8 µm thick PAS stained histological sec-
tions of the tumors. The numbers of ocular grid intercepts
were scored over the area of: blood vessels and capillaries,
endothelial pseudopods and over the area with no indica-
tion of these structures. This method has been shown to
be a usable measure of volume density occupied by recog-
nizable structures. The results of the scoring of blood ves-
sels and of endothelial pseudopods in the subcortical
regions of the tumors are summarized in Fig. 6A&6B. Sta-
tistical analysis of the mean blood vessel volume density
versus the pseudopod volume density reveals a significant
exponential correlation coefficient of 0.966. Thus, as the
blood vessel volume density decreased, the endothelial
pseudopod volume density increased. As illustrated in Fig.
6A&6B, IR resulted in significantly reduced blood vessel
volume density but a significantly increased volume den-
sity of pseudopods at one day after the last dose of irradi-
ation, but the blood vessel volume density increased and
the pseudopod volume density decreased to the level of
the untreated control by 22 days after the last dose of irra-
diation. However, the groups of mice treated solely with
EMF had significantly less blood vessel volume density
Body weights during the course of the experimentFigure 1
Body weights during the course of the experiment. The two groups of mice that received gamma irradiation both lost body 
weight during and for a few days after the course of exposure, but the body weights later recovered towards the weights of 
the two groups of mice not exposed to gamma irradiation.
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and a significantly higher pseudopod volume density at
one day after the end of IR. The low blood vessel volume
density and the high pseudopods volume density in the
tumors of the EMF treated mice remained the same at 22
days after the end of the IR treatment.
Metastasis
The number of lung metastatic colonies per mouse in each
of the four treatment groups is summarized in Fig. 7. Both
the mean number of colonies in the lungs per mouse as
well as the incidence of metastasis was significantly higher
in the untreated group than in the three groups treated
with IR and/or EMF therapy. There were no significant dif-
ferences between the three treatment groups in number or
in incidence of lung metastatic colonies per mouse.
Side Effects of Gamma Irradiation Therapy and of TEMF 
Therapy
Mice were euthanized at both one day and at 22 days after
the last IR exposure. Data on liver and spleen weights are
summarized in Table 1, and data on blood counts are
summarized in Table 2. There were no statistically signifi-
cant differences between treatment groups in mean liver
weights at the earlier or later kills. On the other hand, the
spleen weights of mice that were euthanized one day after
their last exposure to IR were significantly less than the
spleen weights of the non-gamma irradiated groups. The
mean spleen weights of the IR mice recovered to the level
of the untreated groups by 22 days after their last IR expo-
sure. There was no significant loss of spleen weight at the
time of early or at the time of late euthanasia due to TEMF
therapy.
Illustrates the effect on tumor growth of: the 8-day course of gamma irradiation therapy (IR), the daily exposure to the TEMF therapy (TEMF), a combination of gamma irradiation and TEMF ther py (TEMF/IR), and no treatment (Control)Figu e 2
Illustrates the effect on tumor growth of: the 8-day course of gamma irradiation therapy (IR), the daily exposure to the TEMF 
therapy (TEMF), a combination of gamma irradiation and TEMF therapy (TEMF/IR), and no treatment (Control). The tumors 
were all 35 mm3 or less at the start of treatment. The growth rate is the slope of the linear regression of the tumor volumes at 
each time. It can be seen that tumor growth was beginning to deviate from the linear fit about 18 days after the start of TEMF 
or radiation treatments however there was still a reasonable linear fit. ANOVA was used to determine any statistical differ-
ences in growth rates between treatment groups. Different letters demonstrate significant differences. Gamma irradiation 
alone (IR) or in combination with TEMF (TEMF/IR) reduced the tumor growth. The TEMF therapy resulted in a slower tumor 
growth rate than the untreated controls but not as slow as the gamma irradiated mice.
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There was a significant decrease in WBC, RBC, and plate-
lets counts attributed to gamma irradiation exposure at 1
day after the end of radiation treatment (Table 2). There
was no significant difference in WBC, RBC, and platelets
counts attributed to TEMF treatment. At 22 days after the
end of the IR treatment, the WBC and RBC counts in the
two IR groups were not quite as low but remained signifi-
cantly lower than in the two non-irradiated groups while
the IR groups had significantly higher platelet counts than
any of the other groups. Clearly, platelet counts have
made a significant compensatory rebound by 22 days
after the end of IR therapy. Statistical analysis of micronu-
clei counts indicated that there was no significant genoto-
xic damage due to either treatment at either time of
euthanasia.
Another measure of possible side effects was the scoring of
mitotic activity in the duodenal crypts. Fig. 8 summarizes
results of mitotic activity in the duodenal crypts of mice
sacrificed one day after the end of the IR therapy regimen.
The two groups of mice treated with IR 24 hours previ-
ously had significantly fewer metaphase figures per crypt
than the non-treated group or to the group of mice treated
solely with the course of TEMF therapy.
All mice treated with IR demonstrated a tan skin discolor-
ation immediately after the 8-day course of IR therapy, but
the tan skin color returned to the normal skin color by 22
days after the course of IR therapy was terminated. The
skin color in the two non-irradiated groups of mice
remained normal in appearance throughout the course of
the study.
Discussion
On tumor vascularization
The immunohistochemical localization of hypoxia
induced factor (HIF) in the tumors helped explain the vas-
cular pattern of the encapsulated tumors. The HIF positive
reactivity in the tumor was localized to the subcortical
areas of the tumor in the same area found to have the
Mean ± SEM tumor growth rate data from day 7 to day 15 post IR therapy in each treatment groupFigure 3
Mean ± SEM tumor growth rate data from day 7 to day 15 post IR therapy in each treatment group. ANOVA was used to 
determine any statistical differences in growth rates between treatment groups. Different letters demonstrate significant differ-
ences. Tumors in the untreated control group grew significantly faster than did tumors in the other three groups. Tumors in 
the IR/TEMF group had a growth rate significantly lower than that of the other three groups.
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most blood vessels, capillaries and pseudopods. These
observations suggest that this subcortical area of the
tumor is hypoxic leading to production of angiogenesis
growth factors, which in turn acts on the host endothelial
cells to sprout pseudopods. Sprouting of cultured
endothelial cells in response to vascular endothelial
growth factors is known to occur [4]. Feraud et al. also
reported that this endothelial cell sprouting could be
inhibited by several angiostatic agents. The presence of
pseudopodal like structures in viable areas of a tumor
immediately adjacent to necrotic areas of the tumor has
been previously reported [5]. The lack of HIF reactivity in
the cortical area beneath the well vascularized tumor cap-
sule suggest this cortical area is not hypoxic and not in
need of an extensive vasculature. It appears that the PSA
staining of endothelial cell sprouting pseudopods in
tumors gives quantifiable spatial information on where in
the tumor that HIF and vascular endothelial growth fac-
tors are located.
Action of IR and of EMF therapies
EMF therapy has been reported to slow tumor growth and
tumor angiogenesis and to increase the survival time of
tumor bearing mice [1]. An experiment was therefore
designed to test if the combining of IR therapy and EMF
therapy in a tumor bearing mouse model might give an
addictive therapeutic index.
Over half of all cancer patients are given ionizing radia-
tion (IR) during their course of treatment [6]. The interac-
tions between IR and tumor vascularization are complex
[7,8]. It has been shown that IR therapy is dependent on
tumor vascularization and that IR therapy initially inter-
feres with tumor vascularization leading to tumor hypoxia
[9]. However hypoxic areas are radio-resistant until they
can induce angiogenesis and re-oxygenation. Hypoxic
areas of tumors produce HIF leading to production of ang-
iogenesis growth factors, which stimulate angiogenesis to
allow further tumor growth. This known sequence of
events following an IR treatment of a tumorous patient
has lead to the combined use of IR therapy coupled to use
of an anti-angiogenesis agent. By blocking angiogenic fac-
tors, like VEGF, and by blocking the formation of new ves-
sels in combination with IR therapy researchers have
dramatically increased the efficacy of IR therapy in a
number of tumor types [7-9]. The use of anti-angiogenic
agents has proved useful in the treatment of cancer pro-
gression in most preclinical and clinical trials [10,11].
However the prevention of metastasis (Inoue et al.) by
anti-angiogenic agents [11,12] has not gone unchallenged
[[13] and see rebuttal by Kieran et al. [14]].
The experimental results indicate that either IR therapy or
EMF therapy suppressed tumor growth. The IR therapy
proved to be more effective at suppressing tumor growth
than did the EMF therapy while the IR therapy but not the
EMF therapy had harmful side effects. Both IR therapy and
EMF therapy reduced blood vessel volume density within
the tumor when measured one day after the end of the IR
therapy but blood vessel volume density in tumors of the
IR treated mice returned to pre IR treatment levels. The
continual use of daily EMF therapy in the IR treated mice
did suppress the return of blood vessel volume density
within the tumor following IR therapy. The combination
of both therapeutic modalities therefore led to a sustained
and significant reduction in the extent of tumor blood ves-
sel volume density.
That pseudopod volume density was relatively high at 22
day after IR in the group of mice that were on sustained
daily EMF therapy suggests that major areas of these
tumors were anoxic and thus were producing HIF and
VEGF's resulting in the sprouting of the endothelial cell
pseudopods. This indicates that these early events in the
angiogenesis process were not suppressed by the
continued use of EMF therapy. Because continued use of
EMF did suppress tumor blood vessel volume density at
22 days after IR therapy the EMF therapy may be acting to
Relationship between color of the tumor as observed through t e skin and the measur d tumor volumeFigure 4
Relationship between color of the tumor as observed 
through the skin and the measured tumor volume. Tumors 
<35 mm3 were mostly white while tumors >35 mm3 were 
pink.
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Photomicrographs illustrating the pattern of the tumor vascular network (A and B), of endothelial pseudopods stained with AS (C) and wit  CD-31 specific endothelial markers (D), and of the localization of HIF-α (E and F)Figure 5
Photomicrographs illustrating the pattern of the tumor vascular network (A and B), of endothelial pseudopods stained with 
PAS (C) and with CD-31 specific endothelial markers (D), and of the localization of HIF-α (E and F). A, The tumor capsule (left) 
reveals blood vessels. The cortex under the capsule reveals no blood vessels and few endothelial pseudopods while the sub-
cortical area to the right has more pseudopods. B, The subcortical area of the tumor reveals a small blood capillary with multi-
ple endothelial pseudopods protruding at right angles into the tumor mass. C, At high magnification endothelial pseudopods 
are seen to branch and occasionally have a vacuole/lumen (arrow). D, The endothelial pseudopods react positively to the CD-
31 specific endothelial marker. The CD-31 antibody identifies endothelial cells using the avidin-biotin peroxidase complex 
method. E, Viable cell area can be seen beneath tumor capsule (left). Necrotic area can be seen to the right. F, Enlarged sub-
cortical area from E. In E the hypoxic area between the viable and the necrotic tissue is stained brown.
B
C D
E F
A
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Quantification of changes in tumor vascularization between treatment groupsFigure 6
Quantification of changes in tumor vascularization between treatment groups. A and B, The percent of areas (volume density) 
of blood vessels and the percent of area of endothelial pseudopods were determined using an ocular grid intercept counting 
method. The mean ± SEM of each treatment group is graphed. Columns that do not share a common letter within a graph are 
significantly different (p < 0.01). The data indicate that gamma irradiation and EMF alone or in combination decreased the total 
area of blood vessels and increased the total area of pseudopods compared to the control. Data from the untreated mice 
(Control) and the EMF treated mice (TEMF) were pooled from mice from the early and from the late sacrifice because there 
was no significant time of sacrifice difference within these groups.
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suppress one of more of the later steps in the process of
tumor vascularization such as: endothelial cell prolifera-
tion, lumen formation, generation of vascular tubes and
initiation of blood flow [15].
As illustrated in Fig. 6A, the continued daily use of TEMF
following the course of IR therapy suppressed tumor
blood vessel volume density compared to mice given the
IR therapy alone. The data on tumor growth rate, begin-
ning a week after IR therapy, revealed that the continua-
tion of TEMF therapy suppressed the mean tumor growth
rate of the tumors compared to those of mice treated only
with IR therapy. In fact, linear regression analysis of the
data indicates that the slope of the tumor growth rate of
the IR plus TEMF treated mice did not differ from a slope
of zero. Thus, these tumor growth rate results indicate a
significant treatment advantage for continuous daily
TEMF therapy following a standard course of IR therapy.
Since the extent of tumor vascularization has been posi-
tively linked to the likelihood of tumor cell metastasis
[12,16-18] it was anticipated that a decrease in the blood
vessel volume density in the tumor, as observed in the
experiments reported herein, would decrease the chance
for tumor cells to metastasize to distant sites in the tumor
bearing mouse model used in the study. Inspection of the
incidence of metastasis observed in the lungs of human
breast cancer xenographs revealed: that IR therapy alone
reduced metastasis by 49%, that EMF therapy alone
reduced metastasis by 54% while the combination of IR
Metastasis of GFP-expressing human breast MDA MB231 cells from the site of inoculation in the inguinal mammary fat pad to lodge in the lungs of mice  each of the four treatment groupsFigure 7
Metastasis of GFP-expressing human breast MDA MB231 cells from the site of inoculation in the inguinal mammary fat pad to 
lodge in the lungs of mice in each of the four treatment groups. The lungs were removed and smashed between microscopic 
slides and microcolonies of GFP cells were observed by epilumination using blue light and detected by presence of green fluo-
rescence microcolonies observed using both 3.5× and 10× objective lens. The untreated mice had a significantly higher number 
of GFP positive microcolonies than the groups of mice that received gamma irradiation therapy or those mice that received 
EMF therapy. There were no other significant differences between groups in either mean number of microcolonies per lung or 
in incidence. Horizontal lines indicate mean values for each treatment group.
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and EMF therapies when followed by daily EMF therapy
resulted in a 73% reduction in incidence of metastasis to
the lung. Although all three of these therapy regimens
caused a significant decrease in incidence of metastasis of
tumor cells to the lungs the greatest decrease, although
not statistically significant, was with the combination of
IR and EMF therapies.
In summary the results indicate that sustained EMF ther-
apy by itself reduced: the extent of tumor blood vessel vol-
ume density, the tumor growth rate and tumor cell
metastasis to the lung, without harmful side effects. TEMF
therapy alone may therefore be a useful alternate therapy
for cancer patients who decide not to undergo standard
radiation or for chemotherapy. The IR therapy alone
markedly reduced: the tumor growth rate, reduced tumor
metastasis but only transitly reduced tumor blood vessel
volume density. The IR therapy did however have harmful
side effects. These side effects could be minimized by tar-
geted IR exposure. The combination of IR therapy and
continued TEMF therapy markedly suppressed the return
of blood vessel volume density and tumor growth
Table 1: Gamma Irradiation Therapy (IR) and Therapeutic Electromagnetic Field Therapy (TEMF) on Liver and Spleen Weight 
(Means ± SEM)
Therapy Group n Liver weight (grams) Spleen weight (grams)
Early1
Control 5 0.94 ± 0.04 0.107 ± 0.009
IR 5 0.87 ± 0.07 0.031 ± 0.004
TEMF 5 1.04 ± 0.05 0.110 ± 0.006
TEMF/IR 5 0.93 ± 0.04 0.033 ± 0.004
Late2
Control 9 1.26 ± 0.07 0.166 ± 0.008
IR 20 1.17 ± 0.03 0.146 ± 0.008
TEMF 10 1.16 ± 0.05 0.145 ± 0.012
TEMF/IR 10 1.15 ± 0.05 0.151 ± 0.014
1Mice sacrificed one day after last irradiation treatment.
2Mice sacrificed 22 days after last irradiation treatment.
Results of Statistical Analyses:
1. Liver weight: No significant differences among treatment groups.
2. Spleen weight: At early kill, groups treated with gamma irradiation show significant (p < 0.01) loss of weight compared to groups not treated with 
gamma irradiation. In late kill, no significant differences were detected.
Table 2: Gamma Irradiation Therapy (IR) and Electromagnetic Field Therapy (TEMF) on Blood Counts(Means ± SEM)
Therapy Group n WBC × 103/µL RBC × 106/µL Platelets × 103/µL Micronuclei (%RBC)
Early1
Control 4 2.91 ± 0.83 9.08 ± 0.07 584 ± 76 1.3 ± 0.04
IR 4 0.11 ± 0.01 7.50 ± 0.16 389 ± 17 1.2 ± 0.03
TEMF 5 2.89 ± 0.60 9.05 ± 0.12 505 ± 61 1.3 ± 0.04
TEMF/IR 4 0.23 ± 0.06 7.68 ± 0.13 443 ± 34 1.2 ± 0.03
Late2
Control 8 1.85 ± 0.37 8.30 ± 0.14 551 ± 83 1.6 ± 0.06
IR 13 1.48 ± 0.332 7.06 ± 0.16 973 ± 98 0.7 ± 0.01
TEMF 11 1.15 ± 0.29 8.85 ± 0.22 613 ± 62 0.7 ± 0.01
TEMF/IR 10 1.07 ± 0.13 6.58 ± 0.11 1007 ± 141 0.6 ± 0.01
1Mice sacrificed one day after last irradiation treatment.
2Mice sacrificed 22 days after last irradiation treatment.
Results of Statistical Analyses:
1. At the end of irradiation therapy plus one day, gamma irradiation caused significant decreases in WBC, RBC, and platelet counts. No other 
significant differences at p < 0.01.
2. At the end of irradiation therapy plus 22 days, gamma irradiation caused significant decreases in WBC and RBC counts and a significant increase 
in platelet counts. No other significant differences at p < 0.01.
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following IR therapy and resulted in the lowest incidence
of tumor metastasis. Thus these findings support the ideas
that TEMF of the type used in this experiment may be an
effective antiangiogenic therapy and that a combination
of an anti-vascular modality, such as TEMF, with IR ther-
apy may enhance the therapeutic index of IR therapy for
cancer.
Materials and methods
Animals
Female athymic nude mice (purchased from the Harlan
Sprague Dawley, Inc., Indianapolis, IN), 6 weeks of age,
were used for this study. The animals were housed under
pathogen-free conditions and fed an AIN-76 semipurified
diet slightly altered to contain 10% w/w corn oil.
Cell Lines
Human breast cancer cell line MDA-MB-231 was obtained
from the American Type Culture Collection. To determine
the effect of the treatments on the metastatic potential of
the MDA-MB-231 cells they were stably transfected with
the enhanced GFP expression plasmid, pEGFP-N1 (Clon-
tech Laboratories, Inc.). The expression of GFP allowed
for detection of micrometastatic colonies on the whole
flattened lungs with a fluorescence epilumination
microscope. The cell lines were cultured in McCoys's 5A
medium supplemented with pyruvate, vitamins, amino
acids, antibiotics, and 10% fetal bovine serum [2].
HDMECs and the culture medium EGM-2 Mv were main-
tained at 37°C in a humidified incubator with 5% CO2.
In Vivo Tumor Growth
The MDA-MB-231/GFP cells were harvested from expo-
nential cultures and inoculated at 2 × 106 cells/inoculum
in the inguinal mammary fat pad area of female athymic
nude mice, 6 weeks of age. When the tumors grew to an
average diameter of about 3 mm after 5 weeks, the mice
were divided into 4 groups such that the mean and
median of tumor volume of the four groups were closely
matched. Growth of each xenograft was monitored by
externally measuring tumors in three dimensions using
digital calipers 3 times per week. Xenograft volume (V)
Number of metaphase figures per midaxial histological section of duodenal cryptsFigur  8
Number of metaphase figures per midaxial histological section of duodenal crypts. Column height indicates mean ± SEM. The 
data are from the mice sacrificed one day after the last gamma irradiation exposure. The columns that do not share a common 
letter are significantly different. Gamma irradiation but not EMF decreased the number of metaphase figures in the duodenal 
crypts.
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was determined by the following equation: V = (L × W2) ×
0.5, where L is the length and W is the width of a
xenograft.
Gamma Irradiation (IR) Therapy
Eighty tumor-bearing mice received a cumulative dose of
800 cGy of IR (200 cGy each third day for 4 cycles). The
200 cGy/day dosage is based on the results from a prelim-
inary dose response study using the same mouse model
and on the fact that 180 to 250 cGy/day is the commonly
used acute dose for radiotherapy of humans. About 815
cGy whole body radiation is the LD50/30 for mice (50%
lethal within 30 days). Mice were irradiated in a 137Cs
Gamma Cell-40 Irradiator (Atomic Energy of Canada)
facility in our Department of Radiology. Dosimetric anal-
yses for this instrument is performed monthly for
calculation of a precise 200 cGy exposure. Mice were
transferred to a circular cage with individual compart-
ments for each mouse during irradiation. Mice were euth-
anized at one day or 23 days after the last radiation
treatment. The peripheral blood, duodenum, lungs, liver,
spleen and tumor were harvested for analyses and the car-
casses frozen in liquid nitrogen and stored at -20°C for
later analysis of metastasis.
Magnetic Field Therapy
A therapeutic electromagnetic field (TEMF) system having
a proprietary signal devised by EMF Therapeutics, Inc.
(Chattanooga, TN, USA) was used. The system generates a
pulsating half sinewave magnetic field with a frequency of
120 pulses per second [1]. An ellipsoidal coil with 21"
major axis and 14" minor axis was used to generate the
magnetic field. In the experiment reported here, the mag-
netic flux density measured in the exposure chamber was
15 mT. This value of magnetic field flux density was cho-
sen based upon our previous experience and data [1]. A
thorough 3-D mapping of the magnetic filed was per-
formed for the entire space covered by the coil. The flux
density of the magnetic field in the exposure chamber (25
cm long, 10 cm wide and 13 cm high) was consistent
within the entire volume of the chamber. The walls of the
exposure chamber were perforated to allow air exchange
and to limit the temperature change inside the exposure
chamber during the TEMF treatment was less than 1°C.
Euthanasia and Tissue Handling
Mice were deeply anesthetized using a ketamine/rompun
mixture prepared by the UTHSCSA Laboratory Animal
veterinarian, cervically dislocated, then were exsanguin-
ated by cardiac puncture. Blood was collected into an
EDTA containing microtube for complete blood counts.
The tumor, duodenum, spleen and liver were removed at
the time of euthanasia while the carcass (including the
lungs) was frozen and stored at -20°F for later analyses.
Sections of the duodenum, the tumor, and a lobe of liver
were fixed in Omni Fix II (Mt. Vernon N.Y.) and paraffin
embedded. Embedded tissues were cut 4 µm or 8 µm
thick, cut sections were placed on microscope slides then
deparafinized and stained with hematoxylin and eosin or
with periodic acid-Schiff (PAS) for morphological analy-
sis. Additional sections were prepared for
immunohistochemistry.
Metastasis studies
Lungs were removed from the thawed carcass to examine
any spontaneous metastasis. The lungs were placed on a
25 × 75 mm microscope slide then smashed with a second
slide to an area of about 100 mm2. The smashed lungs
were secured in the flattened condition by rapping Magic
tape (Scotch) around each end of the smashed lung prep-
aration. The GFP-expressing metastatic cancer cell colo-
nies, if any, were identified and counted using a Zeiss
fluorescence microscope (TE-200) with a 3.5× and a 10×
objective. GFP micrometastatic sites with three or more
cells were scored as positive. No large metastatic sites were
observed in the lungs.
Tumor Vascularity
To determine the effect of treatment on tumor angiogen-
esis, we measured the vascularity of excised tumors.
Tumor tissues were fixed and imbedded in paraffin. Mid
tumor sections of 8 µm were cut from the embedded
tissue and stained with periodic acid Schiff (PAS). Sec-
tions were examined by light microscopy. CD31 immu-
nostaining for mouse blood vessels was performed by
incubating tumor sections with a rat antimouse CD-31
(PECAM-1) monoclonal antibody (PharMingen) at 5 µg/
ml for 30 min at 37°C. Sections were then incubated with
a biotin-labeled goat antirat IgG (Zymed; 1:200 dilution)
for 30 min at room temperature, followed by ABC reagent
kit (Vector Laboratories) for 30 min at room temperature.
Color reaction was performed with 3, 3'-diaminobenzi-
dine (Vector Laboratories) and counterstained with
hematoxylin. Hypoxia-inducible factor-1 alpha immuno-
histochemistry was done following the instruction for
antigen retrieval (Biogenex protocol) and iso-IHC (inno-
Genex Mouse-on-mouse iso-IHC kit) with these changes:
Dewaxing was with 3 changes of xylene, 10 minutes/
change. Rehydration in 100%, 90%, and 70% ethanol, 10
minutes each. Initial dilution of the antibody was 1:200.
Antibody: Stressgen anti-HIF-1 alpha, product # OSA-601.
All sections were coded, then treated as above and the
extent of blood vessels, endothelial cell pseudopods and
total area volume density was scored using an ocular grid.
The number of grid line intercepts over blood vessels and
endothelial pseudopods gave a measure of the total vol-
ume density of these structures.
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Assays Performed
Complete and differential blood counts
A blood cell counter with veterinary pack was used for
counts of red cells, white cells and platelets in EDTA anti-
coagulated blood of the mice. Our Laboratory Animal
Resources division performed this test.
Peripheral blood micronuclei
At least 1000 acridine orange stained cells were counted
and the percentage of erythrocytes containing micronuclei
was determined [3].
Histological analyses of duodenum
Fixed specimens of duodenum were trimmed, processed
and oriented for paraffin embedding. Four µm thick sec-
tions of the paraffin blocks were mounted on slides. Com-
plete midaxially sectioned crypts on H&E stained slides
were selected for analyses. Complete crypts were defined
as those with: 1) the crypt base at the muscularis mucosa,
2) an open lumen from mouth to base and 3) a single col-
umn of epithelial cells up each side of the crypt. The num-
bers of metaphase figures per midaxial crypt section was
counted for 10 crypts of each mouse.
Statistical analyses
SAS computer software was used for statistical analyses.
Tests for normality (basic statistics) was used on each data
set. One way and two way analyses of variance followed
by Student-Newman-Keuls multiple range tests, as appro-
priate, was used to determine if there were statistically sig-
nificant (p ≤ 0.05) differences in any measured parameter
due to the therapies. Tumor volume change for each
tumor was determined using least squares linear regres-
sion analysis of tumor volume using Prism™ (Graphpad
Software, Inc.). Differences in the proportions of mice
with lung metastatic sites were assessed using the Fischer
exact test analyses.
The abbreviations used
GFP, green fluorescent protein; TEMF, therapeutic electro-
magnetic field; PAS, periodic acid Schiff; HIF, hypoxia
inducible factor 1- alpha; CD-31, monoclonal antibody
against endothelial cells; IR, ionizing irradiation
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